Huons Receives Approval for Phase 3 Clinical Trial Plan of Nano-Composite Eye Drops in Germany
[Asia Economy Reporter Geum Bo-ryeong] Huons announced on the 4th that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the "randomized, double-masked, placebo-controlled, multicenter Phase 3 clinical trial plan to evaluate the efficacy and safety of HU007 eye drops in patients with moderate to severe dry eye syndrome."
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- "All Major Corporations Could Leave"... Business Community Fears Overseas Factory Relocation Due to Strike Risks
- Central Labor Relations Commission Chair: "Mediation Proposal Unlikely Today"... Second Post-Adjustment Talks Between Samsung Electronics Labor and Management Extended Until the 19th
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Huons explained, "Currently, among dry eye treatments with cyclosporine as the main ingredient, only one product is approved and used as a prescription drug in the European market, so we expect economic benefits in the European market."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
